These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 2412052)

  • 21. Effect of chronic ketanserin treatment on serotonin-induced platelet aggregation in patients with Raynaud's phenomenon.
    Marasini B; Biondi ML; Mollica R
    Eur J Clin Pharmacol; 1990; 39(3):289-90. PubMed ID: 2257869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of ketanserin on blood pressure and platelet aggregation in elderly men with mild hypertension.
    Egan B; Conlon ME; Campbell R; Schork N; Zwiefler A; Julius S
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):324S-330S. PubMed ID: 3415805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of dietary salt restriction on urinary serotonin and 5-hydroxyindoleacetic acid excretion in man.
    Sharma AM; Schorr U; Thiede HM; Distler A
    J Hypertens; 1993 Dec; 11(12):1381-6. PubMed ID: 7510737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ketanserin: a possible tool for studying the role of serotonin in hypertension.
    Woittiez AJ; Wenting GJ; Man in't Veld AJ; Boomsma F; Schalekamp MA
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S130-6. PubMed ID: 2412035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparative and long-term evaluation of ketanserin in the treatment of essential hypertension.
    Hedner T; Persson B; Berglund G
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S148-53. PubMed ID: 2412038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical studies with ketanserin in hypertension.
    Waal-Manning HJ; Brown SA; Spears GF; Simpson FO
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S154-8. PubMed ID: 2412040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension.
    Hosie J; Stott DJ; Robertson JI; Ball SG
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S86-8. PubMed ID: 2446081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular effects of ketanserin, a new antiserotonergic agent in the treatment of arterial hypertension.
    Ferrara LA; Fasano ML; Soro S; Rubba P; Iannuzzi A
    J Clin Pharmacol; 1985 Apr; 25(3):187-92. PubMed ID: 3158674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double-blind comparison of ketanserin with atenolol: antihypertensive activity and effect on platelet function.
    Kirch W; Ohnhaus EE
    J Hypertens Suppl; 1986 Apr; 4(1):S67-71. PubMed ID: 2939216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of ketanserin administration on lipid metabolism and platelet aggregation in hypertensive patients.
    Loschiavo C; Valvo E; Bedogna V; Casagrande P; Graziani MS; Nicoli M; Maschio G
    Int J Clin Pharmacol Ther Toxicol; 1990 Nov; 28(11):455-7. PubMed ID: 2272704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension.
    Hedner T; Persson B; Berglund G
    Br J Clin Pharmacol; 1983 Aug; 16(2):121-5. PubMed ID: 6615685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antihypertensive effects of ketanserin and ritanserin in the spontaneously hypertensive rat.
    Persson B; Gradin K; Pettersson A; Hedner T
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S22-4. PubMed ID: 2459509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension.
    Stott DJ; Saniabadi AR; Hosie J; Lowe GD; Ball SG
    Eur J Clin Pharmacol; 1988; 35(2):123-9. PubMed ID: 3142775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antihypertensive properties of ketanserin in combination with beta-adrenergic blocking agents.
    Hedner T; Persson B
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S161-3. PubMed ID: 2412042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antihypertensive effects of ketanserin in the spontaneously hypertensive rat: mode of action.
    Gradin K; Pettersson A; Hedner T; Persson B
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S110-1. PubMed ID: 2412026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AHR-16303B, a novel antagonist of 5-HT2 receptors and voltage-sensitive calcium channels.
    Barrett RJ; Appell KC; Kilpatrick BF; Proakis AG; Nolan JC; Walsh DA
    J Cardiovasc Pharmacol; 1991 Jan; 17(1):41-53. PubMed ID: 1708055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antagonistic actions of renal dopamine and 5-hydroxytryptamine: endogenous 5-hydroxytryptamine, 5-HT1A receptors and antinatriuresis during high sodium intake.
    Soares-da-Silva P; Vieira-Coelho MA; Pestana M
    Br J Pharmacol; 1996 Mar; 117(6):1193-8. PubMed ID: 8882615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reserpine methonitrate, a novel quaternary analogue of reserpine augments urinary excretion of VMA and 5-HIAA without affecting HVA in rats.
    Sreemantula S; Boini KM; Nammi S
    BMC Pharmacol; 2004 Nov; 4():30. PubMed ID: 15546495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.
    Andrén L; Svensson A; Dahlöf B; Eggertsen R; Hansson L
    Acta Med Scand; 1983; 214(2):125-30. PubMed ID: 6353879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of ketanserin on blood pressure and platelets during cardiopulmonary bypass.
    Lichtenthal PR; Wade LD; Rossi EC
    Anesth Analg; 1987 Nov; 66(11):1151-4. PubMed ID: 3662060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.